{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:54:37Z","timestamp":1789512877296,"version":"build-2803163510"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T00:00:00Z","timestamp":1431907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Auxilium Pharmaceuticals"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2015,10]]},"abstract":"\n Objectives<\/jats:title>\n \n To examine the efficacy of intralesional collagenase\n Clostridium histolyticum<\/jats:italic>\n (\n CCH<\/jats:styled-content>\n ) in defined subgroups of patients with Peyronie's disease (\n PD<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n The efficacy of\n CCH<\/jats:styled-content>\n compared with placebo, assessed from baseline to week 52, was examined in subgroups of participants from the Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies (\n IMPRESS<\/jats:styled-content>\n ) I and\n II<\/jats:styled-content>\n . The subgroups were defined according to: severity of penile curvature deformity at baseline (30\u201360\u00b0 [\n n<\/jats:italic>\n = 492] and 61\u201390\u00b0 [\n n<\/jats:italic>\n = 120]);\n PD<\/jats:styled-content>\n duration (1 to \u22642 [\n n<\/jats:italic>\n = 201], >2 to \u22644 [\n n<\/jats:italic>\n = 212] and >4\u00a0years [\n n<\/jats:italic>\n = 199]); degree of plaque calcification (no calcification [\n n<\/jats:italic>\n = 447], non\u2010contiguous stippling [\n n<\/jats:italic>\n = 103] and contiguous calcification that did not interfere with injection of\n CCH<\/jats:styled-content>\n [\n n<\/jats:italic>\n = 62]); and baseline erectile function (International Index of Erectile Function [\n IIEF<\/jats:styled-content>\n ] scores 1\u20135 [\n n<\/jats:italic>\n = 22], 6\u201316 [\n n<\/jats:italic>\n = 106] and \u226517 [\n n<\/jats:italic>\n = 480]).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Reductions in penile curvature deformity and\n PD<\/jats:styled-content>\n symptom bother were observed in all subgroups. Penile curvature deformity reductions were significantly greater with\n CCH<\/jats:styled-content>\n than with placebo for the following subgroups: baseline penile curvature 30\u201360\u00b0 and 61\u201390\u00b0; disease duration >2 to \u22644\u00a0years and >4\u00a0years; no calcification; and\n IIEF<\/jats:styled-content>\n score \u226517 (high\n IIEF<\/jats:styled-content>\n \u2010erectile function score;\n P<\/jats:italic>\n < 0.05 for all).\n PD<\/jats:styled-content>\n symptom bother reductions were significantly greater in the\n CCH<\/jats:styled-content>\n group for: penile curvature 30\u201360\u00b0; disease duration >4\u00a0years; no calcification; and\n IIEF<\/jats:styled-content>\n score 1\u20135 (no sexual activity) and \u226517 (\n P<\/jats:italic>\n < 0.05 for all).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In this analysis, clinical efficacy of\n CCH<\/jats:styled-content>\n treatment for reducing penile curvature deformity and\n PD<\/jats:styled-content>\n symptom bother was found across subgroups. In the\n IMPRESS<\/jats:styled-content>\n I and\n II<\/jats:styled-content>\n overall, adverse events (\n AE<\/jats:styled-content>\n s) were typically mild or moderate, although treatment\u2010related serious\n AE<\/jats:styled-content>\n s, including corporal rupture or penile haematoma, occurred. Future studies could be considered to directly assess the efficacy and safety of\n CCH<\/jats:styled-content>\n treatment in defined subgroups of\n PD<\/jats:styled-content>\n patients, with the goal of identifying predictors of optimum treatment success.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.13096","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T09:44:21Z","timestamp":1424771061000},"page":"650-656","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Clinical efficacy of collagenase\n Clostridium histolyticum<\/i>\n in the treatment of Peyronie's disease by subgroup: results from two large, double\u2010blind, randomized, placebo\u2010controlled, phase\n III<\/scp>\n studies"],"prefix":"10.1111","volume":"116","author":[{"given":"Larry I.","family":"Lipshultz","sequence":"first","affiliation":[{"name":"Scott Department of Urology Baylor College of Medicine Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Goldstein","sequence":"additional","affiliation":[{"name":"San Diego Sexual Medicine Alvarado Hospital San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen D.","family":"Seftel","sequence":"additional","affiliation":[{"name":"Cooper University Hospital Camden NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Auxilium Pharmaceuticals, Inc. Chesterbrook PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Auxilium Pharmaceuticals, Inc. Chesterbrook PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Tursi","sequence":"additional","affiliation":[{"name":"Auxilium Pharmaceuticals, Inc. Chesterbrook PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur L.","family":"Burnett","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-004-0074-y"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900875"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2007.08.017"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152812798889321"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.00895.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.00949.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.01.090"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12312"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.01850.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-011-0212-2"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.02102.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2012.92"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00063-7"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.544252"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.01081.x"},{"key":"e_1_2_7_17_1","volume-title":"Xiaflex\u00ae (collagenase Clostridium histolyticum) [prescribing information]","year":"2013"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.032"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35998-0"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00651.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.01.087"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2047-2927.2012.00007.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13096","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:57:13Z","timestamp":1761757033000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,18]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/bju.13096"],"URL":"https:\/\/doi.org\/10.1111\/bju.13096","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,18]]},"assertion":[{"value":"2015-05-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}